SAN DIEGO, CA – Sept. 25, 2018 — Neurelis, Inc. today announced that the company has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for Valtoco (diazepam nasal spray) as a treatment for epilepsy patients…Original Article
Neurelis Files New Drug Application for Valtoco (diazepam nasal spray), an Investigational Treatment for Pediatric, Adolescent and Adult Epilepsy Patients
